Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas
Open Access
Abstract
Ruthenium-106 (Ru-106) brachytherapy is an established modality for eye-preserving treatment of choroidal melanoma. To achieve optimal treatment outcomes, there should be a balance between tumour control and the risk of healthy tissue toxicity. In this retrospective study, we examined normal tissue complication probability (NTCP) for visual acuity deterioration and late complications to aid the understanding of dose-dependence after Ru-106 treatments. We considered consecutive patients diagnosed with choroidal melanoma and primarily treated at a single institution from 2005–2014. Treatment plans were retrospectively recreated using dedicated software and image guidance to contour the tumour and determine the actual plaque position. Dose distributions were extracted from each plan for all relevant anatomical structures. We considered visual acuity deterioration and late complications (maculopathy, optic neuropathy, ocular hypertension, vascular obliteration, cataract and retinal detachment). Lasso statistics were used to select the most important variables for each analysis. Outcomes were related to dose and clinical characteristics using multivariate Cox regressions analysis. In total, 227 patients were considered and 226 of those were eligible for analysis. Median potential follow-up time was 5.0 years (95% CI: 4.5–6.0). Visual acuity deterioration was related to optic disc-tumour distance and dose metrics from the retina and the macula, with retina V10Gy showing the strongest correlation. Macula V10Gy was the only dose metric impacting risk of maculopathy, while optic disc-tumour distance also proved important. Optic disc V50Gy had the largest impact on optic neuropathy along with optic disc-tumour distance. Optic disc V20Gy was the only variable associated with vascular obliteration. Lens D2% had the largest impact on the risk of cataract along with older age and the largest base dimension. We found no variables associated with the risk of ocular hypertension and retinal detachment. Visual acuity deterioration and most late complications demonstrated dependence on dose delivered to healthy structures in the eye after Ru-106 brachytherapy for choroidal melanomas.Keywords
Funding Information
- Arvid Nilssons Fond (Charlotte Espensen)
- Synoptik Foundation (Charlotte Espensen)
- Dansk Kræftforsknings Fond (Charlotte Espensen)
- The Danish Eye Research Foundation (Charlotte Espensen)
- Yorkshire Cancer Research Academic Fellowship (L389AA)
This publication has 26 references indexed in Scilit:
- Risk Factors for Radiation Maculopathy after Ophthalmic Plaque Radiation for Choroidal MelanomaAmerican Journal of Ophthalmology, 2010
- Radiation-induced optic neuropathyJournal of Clinical Neuroscience, 2008
- Impact of Dose Rate on Clinical Course in Uveal Melanoma after Brachytherapy with Ruthenium-106Strahlentherapie und Onkologie, 2007
- Visual outcome, local tumour control, and eye preservation after106Ru/Rh brachytherapy for choroidal melanomaActa Oncologica, 2006
- Local tumor control after 106Ru brachytherapy of choroidal melanomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapyBritish Journal of Ophthalmology, 2005
- Ruthenium Brachytherapy for Uveal Melanoma, 1979–2003Survival and Functional Outcomes in the Swedish PopulationOphthalmology, 2005
- Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays)American Journal of Ophthalmology, 2004
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996
- Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.British Journal of Ophthalmology, 1996